Research & Literature

Waldenstrom macroglobulinemia: prognosis and management.

Oza A, Rajkumar SV

Blood cancer journal 2015; (5()):e394 doi:10.1038/bcj.2015.28.

Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature.

Bassarova A, Trøen G, Spetalen S, et al.

American journal of clinical pathology 2015; (143(6)):797-806 doi:10.1309/AJCP6ZODWV1CIDME.

How I treat Waldenström macroglobulinemia.

Treon SP

Blood 2015; (126(6)):721-32 doi:10.1182/blood-2015-01-553974.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.

Poulain S, Roumier C, Venet-Caillault A, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(6)):1480-8 doi:10.1158/1078-0432.CCR-15-0646.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Castillo JJ, D'Sa S, Lunn MP, et al.

British journal of haematology 2016; (172(5)):709-15 doi:10.1111/bjh.13883.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, et al.

Haematologica 2017; (102(1)):43-51 doi:10.3324/haematol.2016.147728.

Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.

Kyle RA, Ansell SM, Kapoor P

Best practice & research. Clinical haematology 2016; (29(2)):179-186 doi:10.1016/j.beha.2016.08.014.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, et al.

JAMA oncology 2017; (3(9)):1257-1265 doi:10.1001/jamaoncol.2016.5763.

[How can we treat Waldenström's macroglobulinemia?]

Mucsi AO, Nagy Z

Magyar onkologia 2017; (61(1)):12-20.

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

Hunter ZR, Yang G, Xu L, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(9)):994-1001 doi:10.1200/JCO.2016.71.0814.

Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.

Sidana S, Rajkumar SV, Dispenzieri A, et al.

American journal of hematology 2017; (92(7)):668-673 doi:10.1002/ajh.24745.

The use of emergency apheresis in the management of plasma cell disorders.

Kalayoglu-Besisik S

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(1)):35-39 doi:10.1016/j.transci.2018.02.014.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, et al.

Annals of hematology 2018; (97(8)):1417-1425 doi:10.1007/s00277-018-3311-z.

Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Kyle RA, Larson DR, McPhail ED, et al.

Mayo Clinic proceedings 2018; (93(6)):739-746 doi:10.1016/j.mayocp.2018.02.011.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, et al.

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(7)):1037-1046 doi:10.2215/CJN.13041117.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, et al.

The New England journal of medicine 2018; (378(25)):2399-2410 doi:10.1056/NEJMoa1802917.

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

Treon SP, Gustine J, Meid K, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(27)):2755-2761 doi:10.1200/JCO.2018.78.6426.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, et al.

American journal of hematology 2018; (93(11)):1384-1393 doi:10.1002/ajh.25254.

Initial Evaluation of the Patient with Waldenström Macroglobulinemia.

Castillo JJ, Treon SP

Hematology/oncology clinics of North America 2018; (32(5)):811-820 doi:10.1016/j.hoc.2018.05.008.

Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing-Neel Syndrome.

Arjunan A, Rai H

Case reports in hematology 2019; (2019()):4075960 doi:10.1155/2019/4075960.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, et al.

Leukemia 2019; (33(11)):2654-2661 doi:10.1038/s41375-019-0431-y.

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ, Moreno DF, Arbelaez MI, et al.

Expert review of hematology 2019; (12(10)):873-881 doi:10.1080/17474086.2019.1649132.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.

Zanwar S, Abeykoon JP, Durot E, et al.

American journal of hematology 2020; (95(3)):274-281 doi:10.1002/ajh.25697.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Owen RG, McCarthy H, Rule S, et al.

The Lancet. Haematology 2020; (7(2)):e112-e121 doi:10.1016/S2352-3026(19)30210-8.

Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.

Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al.

Journal of clinical pathology 2020; (73(9)):571-577 doi:10.1136/jclinpath-2019-206282.

Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.

Zhang LL, Cao XX, Shen KN, et al.

Annals of hematology 2020; (99(8)):1735-1740 doi:10.1007/s00277-020-04123-1.

Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.

Jeong S, Kong SG, Kim DJ, et al.

BMC cancer 2020; (20(1)):623 doi:10.1186/s12885-020-07120-9.

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.

Trotman J, Opat S, Gottlieb D, et al.

Blood 2020; (136(18)):2027-2037 doi:10.1182/blood.2020006449.

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Tam CS, Opat S, D'Sa S, et al.

Blood 2020; (136(18)):2038-2050 doi:10.1182/blood.2020006844.

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.

Treon SP, Meid K, Gustine J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(6)):565-575 doi:10.1200/JCO.20.00555.

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Dimopoulos M, Sanz RG, Lee HP, et al.

Blood advances 2020; (4(23)):6009-6018 doi:10.1182/bloodadvances.2020003010.

Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.

Alouche N, Bonaud A, Rondeau V, et al.

Blood 2021; (137(22)):3050-3063 doi:10.1182/blood.2020007450.

Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.

Ellis S, Brown RF, Thorsteinsson EB, et al.

Psychology, health & medicine 2022; (27(8)):1649-1660 doi:10.1080/13548506.2021.1913756.

The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia.

Dammacco R, Lisch W, Kivelä TT, et al.

Ocular immunology and inflammation 2022; (30(7-8)):1659-1668 doi:10.1080/09273948.2021.1933068.

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.

Kersten MJ, Amaador K, Minnema MC, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(1)):40-51 doi:10.1200/JCO.21.00105.

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.

Leslie LA

Current treatment options in oncology 2021; (22(12)):111 doi:10.1007/s11864-021-00909-1.

Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome.

Saburi M, Saburi Y, Kawano K, et al.

International journal of hematology 2022; (115(4)):585-589 doi:10.1007/s12185-021-03246-z.

Venetoclax in Previously Treated Waldenström Macroglobulinemia.

Castillo JJ, Allan JN, Siddiqi T, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(1)):63-71 doi:10.1200/JCO.21.01194.

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.

Castillo JJ, Sarosiek SR, Gustine JN, et al.

Blood advances 2022; (6(3)):1015-1024 doi:10.1182/bloodadvances.2021006106.

SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.

Thomas SK

Clinical lymphoma, myeloma & leukemia 2022; (22(6)):347-355 doi:10.1016/j.clml.2021.11.014.

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Zanwar S, Abeykoon JP

Therapeutic advances in hematology 2022; (13()):20406207221093962 doi:10.1177/20406207221093962.

IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Khwaja J, D'Sa S, Minnema MC, et al.

Haematologica 2022; (107(9)):2037-2050 doi:10.3324/haematol.2022.280953.

Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation.

Brysland SA, Maqbool MG, Talaulikar D, Gardiner EE

Thrombosis and haemostasis 2022; (122(11)):1843-1857 doi:10.1055/a-1896-7092.

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis.

Lu R, Richards T

Journal of the advanced practitioner in oncology 2022; (13(Suppl 4)):45-56 doi:10.6004/jadpro.2022.13.5.14.

Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.

Dogliotti I, Jiménez C, Varettoni M, et al.

Leukemia 2023; (37(2)):388-395 doi:10.1038/s41375-022-01762-3.

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.

Gertz MA

American journal of hematology 2023; (98(2)):348-358 doi:10.1002/ajh.26796.

Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients.

Buske C, Castillo JJ, Abeykoon JP, et al.

Seminars in hematology 2023; (60(2)):73-79 doi:10.1053/j.seminhematol.2023.03.005.

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

D'Sa S, Matous JV, Advani R, et al.

Seminars in hematology 2023; (60(2)):80-89 doi:10.1053/j.seminhematol.2023.03.003.

Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.

Treon SP, Tedeschi A, San-Miguel J, et al.

Seminars in hematology 2023; (60(2)):97-106 doi:10.1053/j.seminhematol.2023.03.009.

Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.

Kapoor P, Paludo J, Abeykoon JP

Hematology/oncology clinics of North America 2023; (37(4)):671-687 doi:10.1016/j.hoc.2023.04.003.

Future Directions in the Frontline Management of Waldenström Macroglobulinemia.

Buske C, Palomba ML

Hematology/oncology clinics of North America 2023; (37(4)):719-725 doi:10.1016/j.hoc.2023.05.001.

Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies.

Tomkins O, Leblond V, Lunn MP, et al.

Hematology/oncology clinics of North America 2023; (37(4)):761-776 doi:10.1016/j.hoc.2023.04.007.

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Dimopoulos MA, Opat S, D'Sa S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(33)):5099-5106 doi:10.1200/JCO.22.02830.

Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.

Khwaja J, Vos JMI, Pluimers TE, et al.

British journal of haematology 2024; (204(1)):177-185 doi:10.1111/bjh.19112.

New developments in the diagnosis and characterization of Waldenström's macroglobulinemia.

García-Sanz R, Hunter ZR, Poulain S, et al.

Expert review of hematology 2023; (16(11)):835-847 doi:10.1080/17474086.2023.2270779.

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.

Treon SP, Sarosiek S, Castillo JJ

Blood 2024; (143(17)):1702-1712 doi:10.1182/blood.2022017235.

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Adekola K, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(1D)):e240001.

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.

Tam CS, Opat S, D'Sa S, et al.

Blood advances 2024; (8(7)):1639-1650 doi:10.1182/bloodadvances.2023010906.

Optimizing BTK Inhibition in Waldenström Macroglobulinemia.

Sarosiek S, Castillo JJ

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(4)).

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Zanwar S, Le-Rademacher J, Durot E, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(21)):2527-2536 doi:10.1200/JCO.23.02066.

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

Tedeschi A, Tam CS, Owen RG, et al.

Future oncology (London, England) 2024; (20(25)):1789-1798 doi:10.1080/14796694.2024.2355079.

Diagnosis and Risk Stratification in Waldenström Macroglobulinemia.

Zanwar S, Kapoor P

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(7)).

Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia.

Yan Y, Yu Y, Xiong W, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(23)):5483-5493 doi:10.1158/1078-0432.CCR-23-3939.

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Heyman BM, Opat SS, Wahlin BE, et al.

Blood advances 2025; (9(4)):722-728 doi:10.1182/bloodadvances.2024014115.

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management.

Gertz MA

American journal of hematology 2025; (100(6)):1061-1073 doi:10.1002/ajh.27666.

Impact of Comorbidities on Patients With Waldenström Macroglobulinemia in Taiwan: A Multicenter Study.

Chang YS, Tuan YH, Gao JW, et al.

JCO global oncology 2025; (11()):e2400576 doi:10.1200/GO-24-00576.

Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia.

Chen J, Li J, Zhou DB, Cao XX

Leukemia & lymphoma 2025; (66(10)):1922-1930 doi:10.1080/10428194.2025.2505705.

Hyperviscosity Syndrome: An Oncologic Emergency.

Bey T, Qdaisat A

Emergency medicine clinics of North America 2025; (43(3)):445-452 doi:10.1016/j.emc.2025.03.001.

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia.

Castillo JJ, Guijosa A, Allan JN, et al.

Blood advances 2025; (9(19)):4842-4847 doi:10.1182/bloodadvances.2025016890.

SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenström Macroglobulinemia.

Guijosa A, Heras AL, Sarosiek S, Castillo JJ

Clinical lymphoma, myeloma & leukemia 2025; doi:10.1016/j.clml.2025.06.017.

Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.

Buske C, Herold M, Bahar N, et al.

Value in health regional issues 2025; (50()):101162 doi:10.1016/j.vhri.2025.101162.

Diagnosis and management of cold agglutinin disease.

Berentsen S

Hematology. American Society of Hematology. Education Program 2025; (2025(1)):295-304 doi:10.1182/hematology.2025000718.

Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia-A Real-World Study.

Mäkelä E, Vikkula J, Havula E, Anttila P

Clinical lymphoma, myeloma & leukemia 2026; (26(5)):e577-e585.e3 doi:10.1016/j.clml.2025.12.006.

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.

Yan Y, Chen W, Yu Y, et al.

Leukemia 2026; (40(6)):1203-1213 doi:10.1038/s41375-026-02919-0.

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.

Banerjee Nair S, Hyun TS, Naresh KN

Journal of clinical pathology 2026; (79(6)):363-369 doi:10.1136/jcp-2026-210690.

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Palomba ML, Patel MR, Eyre TA, et al.

The Lancet. Haematology 2026; (13(5)):e284-e296 doi:10.1016/S2352-3026(26)00037-2.

68 Ga-pentixafor PET/CT Indicates Inconsistent Response With Monoclonal Protein-based Response Criteria in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Patients Treated With Bruton Tyrosine Kinase Inhibitors.

Pan Q, Liu S, Zhang H, et al.

Clinical nuclear medicine 2026; (51(8)):637-643 doi:10.1097/RLU.0000000000006518.

Cold agglutination as a pivotal diagnostic clue for Waldenström macroglobulinemia: A rare case report with diagnostic and therapeutic insights.

Zhang W, Xia Y, Yang Z, et al.

Experimental and therapeutic medicine 2026; (32(2)):217 doi:10.3892/etm.2026.13212.

Outcomes of patients with Waldenström macroglobulinemia in ICU: a retrospective multicentric study.

Barraud C, Velletrie A, Harel S, et al.

Journal of critical care 2026; (97()):155731 doi:10.1016/j.jcrc.2026.155731.

Prevalence and Disability of Peripheral Neuropathy in Patients With Waldenström's Macroglobulinemia.

Aagaard MM, Skaastrup KN, Kodal LS, et al.

European journal of haematology 2026; doi:10.1111/ejh.70316.

Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia.

Edwards CV, Castillo JJ, Mouhieddine TH, Sarosiek SR

Expert opinion on pharmacotherapy 2026; 1-14 doi:10.1080/14656566.2026.2734125.